GB2604132A — Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes

USPTO Abstract

Cannabidiol (CBD) for use in the treatment of childhood onset epilepsy in patients who are concurrently taking clobazam characterised in that the patient is monitored for incidence of pneumonia, is provided. Preferably the dose of CBD is between 5 and 50mg/kg/day, and the dose is preferably reduced by 10% and 90%. The dose of clobazam is preferably between 5 and 60mg/kg/day, and the dose is preferably reduced by between 10% and 90%. The CBD may be in the form of a highly purified extract of cannabis which comprises at least 95% (w/w) CBD, or the CBD may be in the form of a synthetic compound. The childhood onset epilepsy is preferably selected from: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex (TSC). A method of treating childhood onset epilepsy in an individual in need thereof, comprising administering to the patient a therapeutically effective amount of cannabidiol with caution, wherein the individual is concurrently taking clobazam is outlined, wherein the caution preferably comprises monitoring the individual for adverse events.